| A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (NCT07407933) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2026-03-31 |
| A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy (NCT07487896) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2026-03-24 |
| Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer (NCT07416994) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2026-03-18 |
| YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (NCT07461454) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2026-03-17 |
| A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (NCT07208773) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2025-10-29 |
| A Study of YL242 in Subjects With Advanced Solid Tumors (NCT07197827) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2025-09-22 |
| A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (NCT07169994) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2025-09-02 |
| A Study of YL202 in Patients With Advanced Solid Tumors (NCT07202364) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2025-08-04 |
| A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors (NCT06859762) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2025-07-02 |
| A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT06629597) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2024-12-31 |
| A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (NCT06612151) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2024-12-17 |
| A Clinical Study of YL205 in Patients With Advanced Solid Tumors (NCT06459973) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2024-06-04 |
| Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (NCT06384352) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2024-05-01 |
| A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors (NCT06394414) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2024-04-17 |
| A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC (NCT06241846) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2024-02-22 |
| A Study of YL202 in Selected Patients With Advanced Solid Tumors (NCT06107686) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2023-12-15 |
| A Study YL201 in Patients With Selected Advanced Solid Tumors (NCT06057922) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2023-09-22 |
| A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer (NCT05653752) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2022-12-20 |
| A Study of YL201 in Patients With Advanced Solid Tumors (NCT05434234) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2022-05-25 |